Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status:
Recruiting
Trial end date:
2025-11-05
Target enrollment:
Participant gender:
Summary
This is a multicenter, open Phase Ib clinical study to evaluate the safety,efficacy and
pharmacokinetics of BEBT-908 combined with Rituximab (R) or combined with
Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) or combined with
Rituximab-Ifosfamide-Carboplatin-Etoposide (R-ICE) in the treatment of Relapsed/Refractory
Diffuse Large B-Cell Lymphoma (R/R DLBCL).